EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Treatment of Dyslipidemia in Patients with Type 1 Diabetes Mellitus: A Review of Current Evidence and Knowledge Gaps

Viviana Elian iD, Alina Dorita, Daniela Stegaru, Dragos Vinereanu iD

International Journal of Molecular Sciences · 03.09.2025 · 26 (17) · 8558

DOI: 10.3390/ijms26178558 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.09.2025. Verfasst von Viviana Elian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes, Nutrition and Metabolic Disease Unit, University of Medicine and Pharmacy Carol Davila, 5-7 Ion Movila Street, 0202475 Bucharest, Romania. Hauptthemen laut MEDLINE: Dyslipidemias, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carol Davila University of Medicine and Pharmacy, University of Medicine and Pharmacy Carol Davila.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes (T1D) is a chronic condition with an increasing prevalence worldwide and a significant improvement in life expectancy in the last decades. T1D confers an increased risk of cardiovascular events, driven by elevated LDL cholesterol (LDL-C) and qualitative lipoprotein abnormalities, such as dysfunctional HDL and smaller, denser LDL-C. Lipid-lowering outcome trials have overwhelmingly focused on type 2 diabetes or the general population, resulting in very limited T1D-specific evidence. Recommendations from major medical associations (ADA, ESC/EAS, ACC/AHA, ISPAD) create additional ambiguity regarding the treatment of dyslipidemia in T1D. This review synthesizes the available evidence on dyslipidemia management in T1D, including published observational cohorts, randomized controlled trials, and international guideline recommendations from January 2000 to June 2025. LDL-C remains the primary modifiable risk factor. Each 1 mmol/L increase is associated with 35–50% greater cardiovascular (CV) risk in T1D cohorts. Statin therapy reduces CV risk by up to 25% in patients with diabetes; however, evidence remains limited in patients with T1D. Ezetimibe provides an additional 18% LDL-C lowering and a 14% event reduction in mixed-diabetes trials, while PCSK9 inhibitors offer a potent 40–60% LDL-C reduction and an 18% MACE reduction. The uptake of statins in eligible adults with T1D remains below 50%. Statins remain the cornerstone of dyslipidemia management in T1D, with emerging evidence supporting ezetimibe and PCSK9 inhibitors. The heterogeneity across international guidelines and the scarcity of T1D-specific outcome data underscore the need for targeted research and evidence-based strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasDiabetes Mellitus, Type 1HumansCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular Diseases

Stichwörter der Autor:innen

PCSK9 inhibitorscardiovascular diseaseclinical guidelinesdyslipidemiaezetimibelipid-lowering therapystatinstype 1 diabetes

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Diabetes, Nutrition and Metabolic Disease Unit, University of Medicine and Pharmacy Carol Davila, 5-7 Ion Movila Street, 0202475 Bucharest, Romania.
  • Diabetes, Nutrition and Metabolic Disease Unit, National Institute of Diabetes, Nutrition and Metabolic Disease Prof. N. C. Paulescu, 020475 Bucharest, Romania.
  • Department of Cardiology and Cardiovascular Surgery, University of Medicine and Pharmacy Carol Davila, 169 Splaiul Independenței, 050098 Bucharest, Romania.
  • Department of Cardiology, University and Emergency Hospital, 050098 Bucharest, Romania.
  • SEARCH-Vasc Centre of Excellence, 050098 Bucharest, Romania.

ORCID-Profile: Viviana Elian, Dragos Vinereanu

Förderung

  • Carol Davila University of Medicine and Pharmacy
  • University of Medicine and Pharmacy Carol Davila

Zitieren

APA

Elian, V., Dorita, A., Stegaru, D., & Vinereanu, D. (2025). Treatment of Dyslipidemia in Patients with Type 1 Diabetes Mellitus: A Review of Current Evidence and Knowledge Gaps. International Journal of Molecular Sciences, 26(17), 8558. https://doi.org/10.3390/ijms26178558

Vancouver

Elian V, Dorita A, Stegaru D, Vinereanu D. Treatment of Dyslipidemia in Patients with Type 1 Diabetes Mellitus: A Review of Current Evidence and Knowledge Gaps. International Journal of Molecular Sciences. 2025;26(17):8558. doi:10.3390/ijms26178558

BibTeX
@article{Elian2025,
  author = {Elian, Viviana and Dorita, Alina and Stegaru, Daniela and Vinereanu, Dragos},
  title = {Treatment of Dyslipidemia in Patients with Type 1 Diabetes Mellitus: A Review of Current Evidence and Knowledge Gaps},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {17},
  pages = {8558},
  doi = {10.3390/ijms26178558}
}
Kostenlos starten →